Victoza® may help your uncontrolled Januvia® (sitagliptin) patients reach an A1C goal of <7% with the additional benefit of weight loss.1
In a head-to-head study vs Januvia® plus metformin, adults with type 2 diabetes experienced 2X greater A1C reductions when switched from Januvia® to Victoza®.1
Safety and tolerability were studied
The adverse events most commonly reported in ≥5% of patients treated with Victoza® 1.8 mg vs Januvia® 100 mg, both in combination with metformin, were nausea (21.8% vs 7.8%), diarrhea (16.3% vs 9.3%), decreased appetite (8.9% vs 3.4%), vomiting (7.4% vs 4.9%), headache (6.4% vs 5.9%), nasopharyngytis (5.9% vs 3.4%), and increased lipase (5.5% vs 4.4%).1
Victoza® provided 3-for-1 benefits
In a 26-week head-to-head study vs Januvia®, Victoza® provided the benefit of significant A1C reductions with the additional benefits of weight change and a low rate of hypoglycemia in adults with type 2 diabetes taking metformin. Victoza® is not indicated for chronic weight management, and weight change was a secondary endpoint in clinical trials.
Individual results may vary.
A 26-week, randomized, parallel group, double-blind, double-dummy, active-controlled study to compare efficacy and safety in patients switching from sitagliptin (100 mg/day) to Victoza® 1.8 mg with patients who stayed on sitagliptin (100 mg/day). Patients with type 2 diabetes inadequately controlled on metformin (≥1500 mg/day) and sitagliptin (100 mg/day) for at least 90 days prior to screening (N=407) were randomized 1:1 to switch to once-daily Victoza® 1.8 mg plus a sitagliptin placebo or continued sitagliptin 100 mg plus a Victoza® placebo, both in combination with metformin.1
References: 1. Bailey TS, Takács R, Tinahones FJ, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH™): a randomized, double-blind, double-dummy, active-controlled 26-week trial [published online ahead of print July 6, 2016]. Diabetes Obes Metab. doi:10.1111/dom.12736.0.